These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25361998)

  • 21. Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma.
    Dorothée G; Echchakir H; Le Maux Chansac B; Vergnon I; El Hage F; Moretta A; Bensussan A; Chouaib S; Mami-Chouaib F
    Oncogene; 2003 Oct; 22(46):7192-8. PubMed ID: 14562047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
    Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
    J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.
    Kudo K; Imai C; Lorenzini P; Kamiya T; Kono K; Davidoff AM; Chng WJ; Campana D
    Cancer Res; 2014 Jan; 74(1):93-103. PubMed ID: 24197131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
    Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
    Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
    J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental treatment strategies in primary cutaneous T-cell lymphomas.
    Rozati S; Kim YH
    Curr Opin Oncol; 2016 Mar; 28(2):166-71. PubMed ID: 26844985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R; Yoshida H; Yanagawa T; Sato M
    J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel xenograft model of cutaneous T-cell lymphoma.
    Krejsgaard T; Kopp K; Ralfkiaer E; Willumsgaard AE; Eriksen KW; Labuda T; Rasmussen S; Mathiesen AM; Geisler C; Lauenborg B; Becker JC; Zhang Q; Wasik MA; Odum N; Woetmann A
    Exp Dermatol; 2010 Dec; 19(12):1096-102. PubMed ID: 20629733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
    Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
    Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
    Katsumi Y; Kuwahara Y; Tamura S; Kikuchi K; Otabe O; Tsuchiya K; Iehara T; Kuroda H; Hosoi H; Sugimoto T
    Clin Cancer Res; 2008 Feb; 14(4):1192-9. PubMed ID: 18281554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.